Browsing by Author "Nechaeva, M."
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P.Item Three Years Survival Outcome And Continued Cemiplimab (CEMI) Beyond Progression With The Addition Of Chemotherapy (Chemo) For Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): The EMPOWER-Lung 1 Trial(2022) Ozguroglu, M.; Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.; Nechaeva, M.; Schenker, M.; Cicin, I.; Ho, G. F.; Kulyaba, Y.; Dvorkin, M.; Zyuhal, K.; Scheusan, R. I.; Li, S.; Pouliot, J-F.; Seebach, F.; Lowy, I.; Gullo, G.; Rietschel, P.